Beyond the interferon score: neurofilament light chain and glial fibrillary acidic protein capture immune-mediated neuroinjury and response to JAK inhibition in Aicardi–Goutières syndrome

Read full text
Authors: Lisa Wege, Christian Klemann, Sandy Siegert, Annette E. Bley, Sarah Koss, Anne Koy, Thorsten Langer, Franziska Dunst, Barbara Plecko, Martin Fleger, Fabian Speth, Tim Niehues
+12 more Peter Kaufmann, Jurek Schultz, Mohammed Attia, Johannes Stoffels, Beata Wolska‐Kuśnierz, Roman Rolke, Gabriele Reichelt, Friederike Blankenburg, Jürgen Brunner, Katja Akgün, Christine Wolf, Min Ae Lee-Kirsch
Cited by: 1
References: 13

Abstract

Background and objective: Aicardi-Goutières syndrome (AGS) is a prototypical type I interferon-driven neuroimmunological disorder in which immune-mediated inflammation causes progressive brain injury. Targeted immunosuppression with Janus kinase (JAK) inhibitors has shown clinical benefit, yet neurological outcomes remain difficult to quantify, and the interferon (IFN) score poorly reflects neuroaxonal damage. We investigated whether plasma neurofilament light chain (pNfL) and glial fibrillary acidic protein (pGFAP) serve as sensitive biomarkers of neurological involvement and response to immunosuppressive therapy. Methods: Plasma samples from 55 patients with genetically confirmed AGS and 55 age- and sex-matched healthy controls were analyzed using single molecule array assays. pNfL and pGFAP levels were assessed in relation to age, clinical disease severity, IFN score, and treatment with JAK inhibitors. Longitudinal samples before and during therapy were available from 11 patients. Results: Treatment-naïve AGS patients exhibited significantly elevated pNfL and pGFAP levels compared with controls, and biomarker concentrations correlated with clinical disease severity. pNfL and pGFAP were strongly correlated with each other but showed only weak to moderate associations with the IFN score. Longitudinal within-patient analyses demonstrated significant declines in pNfL and pGFAP following initiation of JAK inhibitor therapy, whereas the IFN score remained unchanged. Discussion: pNfL and pGFAP are sensitive indicators of neuroaxonal and astroglial injury in AGS, capturing neurological disease burden and treatment-associated changes more accurately than the IFN score. These findings support their use as objective biomarkers for monitoring immune-mediated brain injury and therapeutic response, and warrant validation in larger longitudinal studies.

Fields of Study & Subjects

interferon and immune responses Peripheral Neuropathies and Disorders Ocular Diseases and Behçet’s Syndrome

Publication details

Journal / source
Frontiers in Immunology
Publisher
Frontiers Media SA
Volume
17
Pages
1782352–1782352
Publication date
15 April 2026
Language
EN